Proactive Investors - Run By Investors For Investors
Why invest in GDR?
Genedrive PLC: DEEP DIVE

Genedrive making commercial progress

Here we take a closer look at Genedrive PLC (LON:GDR)
genedrive device
OVERVIEW: GDR The Big Picture
The Genedrive system is easy to use, provides unambiguous results, so doesn’t require specialist knowledge or data interpretation
  • Developed and easy-to-use diagnostic device
  • US Department of Defense is a customer 
  • Well-funded

What the company does

Genedrive has developed and is now commercialising a low-cost, rapid, versatile and simple-to-use diagnostic. The device of the same name has a broad range of applications. However, its HCV-ID variant, for detecting hepatitis-c, has received EU regulatory sign-off in the form of CE Certification and has been launched in Africa and the Asia Pacific region. In development is a model for tuberculosis.

So why is the interesting? Well, the system is able to rapidly process the biologic information from plasma, sputum and buccal swabs. It is easy to use, provides unambiguous results, so doesn’t require specialist knowledge or data interpretation. The company reckons the hand-held Genedrive system is ideal for “low throughput de-centralised labs”.

Inflexion points

  • It won its first order from the US Department of Defense (DoD) and it expects more work from the Americans
  • The HCV ID kit is under review by the World Health Organisation for ‘pre-qualified status’
  • Registrations of the hepatis device is targeted for 30 countries by the year-end

Financial Position and current trading

The half-year results revealed the company had £4.7mln in cash at the end of March. At that point it was waiting for an R&D tax credit and a payment from DoD.

It told investors country registrations for the HCV kit had been slower than anticipated. This delay will have a short-term impact on revenues, it confirmed. Nevertheless, it still expects to post a year-on-year 25% rise in revenues. “The board remains confident in the Genedrive platform, particularly as we move into commercialisation for both our HCV and bio-threats tests, and continue to be committed to the business strategy of exploiting the attractive near patient molecular diagnostics market,” chief executive David Budd said.

What the broker says

The company’s broker Peel Hunt reckons the stock is worth 60p (current price 21p). It reckons the company will post revenues of £2.5mln this year. “Genedrive is clearly benefiting from the strength of its platform as shown by multiple orders from the DoD and several research grants spread over several years,” analyst Miles Dixon said.

View full GDR profile View Profile

Genedrive PLC Timeline

Big Picture
May 23 2019

Related Articles

test tubes
May 03 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use